Irrimax, an Atlanta, GA-based medical device company, received an investment from Decathlon Capital Partners.
The amount of the deal was not disclosed.
The company intends to use the funds for the ongoing development of its medical technology and expand opportunities for its use.
Led by CEO Mark Alvarez, Irrimax invented and developed Irrisept®, an FDA-cleared medical device containing low concentration chlorhexidine gluconate (CHG 0.05%) for irrigation. This proprietary technology is designed to loosen and remove debris without harming underlying tissue during application.
Irrisept helps prevent infections, focusing on Hospital Acquired Infections (HAIs) and, ultimately, improves patient outcomes and reduces healthcare costs.
The device has passed required safety testing for cytotoxicity, skin irritation and immune allergic response.